Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manish Shah

Medical Oncology New York, NY Medical Doctor

NPI 1750473922 CMS profile 306260

1305 York Ave, 12Th Floor, New York, NY 10021

Open in the dashboard

General payments

$306,763

236 records reported · program years 2019–2025

Research payments

$2,428

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,779,688 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Manish Shah of New York, NY is reported in the CMS Open Payments database as having received $306,763 across 236 general payments and $2,428 in research payments paid to them. Separately, studies naming them as principal investigator received $8,779,688 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $41,585 62
2024 General $54,216 41
2023 General $23,966 24
2022 General $12,807 4
2022 Research $1,016 1
2021 General $50,545 24
2020 General $42,923 23
2020 Research $1,413 2
2019 General $80,721 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manish Shah
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Manish Shah were reported at $41,585. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Manish Shah Medical Oncology median Middle half National median
2019 $80,721 $968 $140–$6,658 $163
2020 $42,923 $747 $102–$5,891 $114
2021 $50,545 $430 $50–$4,098 $132
2022 $12,807 $812 $127–$4,907 $149
2023 $23,966 $957 $144–$5,248 $160
2024 $54,216 $1,042 $149–$5,650 $164
2025 $41,585 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $116,152 67 payments
  2. E.R. Squibb & Sons, L.L.C. $32,672 30 payments
  3. Lilly USA, LLC $26,026 6 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $21,524 9 payments
  5. Genzyme Corporation $12,046 12 payments
  6. BeiGene USA, Inc. $10,232 4 payments
  7. Eli Lilly and Company $9,625 2 payments
  8. Daiichi Sankyo Inc. $9,378 9 payments
  9. EMD Serono, Inc. $7,800 1 payment
  10. AstraZeneca UK Limited $7,349 12 payments
  11. Other $53,959 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $226,717 73 payments
  2. Travel and Lodging $50,526 52 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,043 4 payments
  4. Honoraria $8,150 4 payments
  5. Food and Beverage $4,302 102 payments
  6. Education $26 1 payment
Products named General payments · program years 2019–2025
  1. KEYTRUDA $55,589 39 payments
  2. FRUZAQLA $21,524 9 payments
  3. CYRAMZA $19,198 5 payments
  4. TEVIMBRA $10,232 4 payments
  5. ENHERTU $9,378 9 payments
  6. OPDIVO $7,487 10 payments
  7. Lenvima $4,710 2 payments
  8. MEKTOVI $4,028 2 payments
  9. Avastin $3,850 1 payment
  10. TECENTRIQ $3,850 1 payment
  11. Other $7,731 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $2,428 3 payments

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$1,657,686

Of which drugs: $1,378,898

Medicare patients

187

Average age 76

Services billed

104,927

83 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 58%
Arthritis 45%
Ischemic heart disease 44%
Diabetes 39%
Heart failure 26%
Chronic kidney disease 26%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, fluorouracil, 500 mg J9190 Office 32 1,465 $3,328
Injection, leucovorin calcium, per 50 mg J0640 Office 31 808 $2,797
Injection, gemcitabine hydrochloride, 200 mg J9201 Office 15 916 $2,383
Injection, irinotecan, 20 mg J9206 Office 11 841 $1,841
Injection, palonosetron hcl, 25 mcg J2469 Office 37 2,140 $1,477
Injection, oxaliplatin, 0.5 mg J9263 Office 22 23,340 $1,300
Injection, atropine sulfate, 0.01 mg J0461 Office 13 2,510 $167
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 25 1,001 $89
Infusion, normal saline solution , 1000 cc J7030 Office 22 36 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $10,934
$10,934 — —
TEVIMBRA
  • BeiGene USA, Inc. $10,232
$10,232 — —
Lenvima
  • Eisai Inc. $4,710
$4,710 — —
LOQTORZI
  • Coherus Biosciences Inc. $1,200
$1,200 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $111
$111 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record